Understanding the Resistance Associated with Minimal Residual Disease

Acute Myeloid Leukemia (AML) is a difficult cancer to treat effectively. By utilizing in vitro and in vivo approaches, we plan to identify the mechanism by which hypoxia and stromal cell populations uniquely induces resistance in response to frontline therapy of AML cells. Furthermore, we are interested in understanding how treatment of AML with frontline therapy leading to MRD could lead to unique sensitivities to subsequent treatment with alternative therapies, especially to Bcl-2 inhibitors such as Venetoclax.